发明公开
EP3304080A1 METHOD FOR STRATIFICATION OF MELANOMA PATIENTS BY DETERMINATION OF OXYGEN CONSUMPTION, PPARGC1A, PPARGC1B AND MITF LEVELS
审中-公开
通过测定耗氧量，PPARGC1A，PPARGC1B和MITF水平来分层分析梅毒瘤患者的方法
- 专利标题： METHOD FOR STRATIFICATION OF MELANOMA PATIENTS BY DETERMINATION OF OXYGEN CONSUMPTION, PPARGC1A, PPARGC1B AND MITF LEVELS
- 专利标题（中）： 通过测定耗氧量，PPARGC1A，PPARGC1B和MITF水平来分层分析梅毒瘤患者的方法
-
申请号： EP16724899.6申请日： 2016-05-25
-
公开(公告)号： EP3304080A1公开(公告)日： 2018-04-11
- 发明人: HAENDLER, Bernard , GELATO, Kathy Ann , SCHÖCKEL, Laura , HEROULT, Melanie
- 申请人： Bayer Pharma Aktiengesellschaft
- 申请人地址： Müllerstrasse 178 13353 Berlin DE
- 专利权人： Bayer Pharma Aktiengesellschaft
- 当前专利权人： Bayer Pharma Aktiengesellschaft
- 当前专利权人地址： Müllerstrasse 178 13353 Berlin DE
- 代理机构： BIP Patents
- 优先权： EP15169617 20150528
- 国际公布： WO2016189042 20161201
- 主分类号： G01N33/574
- IPC分类号： G01N33/574
摘要：
The present invention refers to a method and kit for stratification of melanoma patients by determining the OCR and levels of PPARGC1A, PPARGC1B and MITF RNA, derived cDNA, or corresponding protein. Especially, the invention is related to stratification kits to determine whether a patient with melanoma will respond to treatment with a BET inhibitor. In a further aspect, the invention is related to the use of a BET inhibitor for the treatment of melanoma in a patient by stratifying a sample of body fluid or tumor tissue in vitro and determining whether a patient suffering from melanoma will respond to treatment with a BET inhibitor.
信息查询
IPC分类:
